Prolymphocytic Leukemia Clinical Trials

63 clinical trials for Prolymphocytic Leukemia across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Allo HSCT Using RIC and PTCy for Hematological Diseases — RECRUITING · PHASE2
• Observatory of Prolymphocytic Leukemia T — RECRUITING
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — RECRUITING · PHASE2
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies — RECRUITING · PHASE2
• Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases — TERMINATED · NA
• Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation — TERMINATED · PHASE2
• ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant — COMPLETED · PHASE3
• PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING
• Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL — COMPLETED · PHASE1
• Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL — COMPLETED · PHASE2
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies — COMPLETED · PHASE2
• UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep — COMPLETED · PHASE2
• Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease — COMPLETED · PHASE2
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant — COMPLETED · PHASE1
• Allo HSCT Using RIC for Hematological Diseases — COMPLETED · PHASE2
• CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy — COMPLETED · PHASE1
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies — COMPLETED · PHASE2
• Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies — TERMINATED · PHASE2
• Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases — COMPLETED · PHASE2
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 — COMPLETED · PHASE1
• Allogeneic Stem Cell Transplant for CLL — TERMINATED · PHASE1
• Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer — COMPLETED · PHASE2
• Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma — COMPLETED · PHASE1
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies — COMPLETED · PHASE2
• Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant — COMPLETED · PHASE2
• Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia — COMPLETED · PHASE2
• Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — COMPLETED · PHASE2
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 — OTHER · PHASE1
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies — COMPLETED · PHASE2
• Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer — COMPLETED
• Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia — COMPLETED · PHASE1
• Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer — COMPLETED · NA
• AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma — COMPLETED · PHASE1
• Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia — COMPLETED · PHASE2
• Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia — COMPLETED · PHASE1
• Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia — COMPLETED · PHASE2
• Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant — WITHDRAWN · PHASE2
• Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers — COMPLETED · PHASE1
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant — TERMINATED · PHASE2
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer — COMPLETED · NA
• Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation — WITHDRAWN · PHASE2
• Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia — TERMINATED · PHASE2
• Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia — TERMINATED · PHASE2
• Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) — COMPLETED · PHASE1
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 — OTHER · NA
• Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — TERMINATED · PHASE1

Refine this search